Sunita Dhar is an Executive Medical Group Director in Clinical Safety and the Franchise head for the I2O portfolio at Genentech. Sunita joined the industry after 12 years of clinical practice and has over seventeen years of experience in drug development, safety science, and pharmacovigilance across multiple therapeutic areas. Prior to joining Roche/Genentech in 2011, she led the drug safety department at a mid-size biopharmaceutical company in the Bay Area. Sunita is passionate about making a positive impact on the growth and development of colleagues, bringing transformative therapies to patients, and improving patient access beyond regulatory approval through new innovative tools, technology, and smart data analytics.